ArticleDrug design, development and therapy2026
Olanzapine-Associated Hepatotoxicity in Bipolar Disorder: A Multicenter Real-World Study of Prevalence, Risk Factors, and Outcomes.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Olanzapine, an atypical antipsychotic agent, is widely used in the treatment of bipolar disorder due to its multifaceted therapeutic effects, encompassing sedation, mood stabilization, and antidepressant activity. Nevertheless, safety concerns remain a critical consideration in clinical application. Objects: This real-world, multicenter retrospective cohort study aimed to investigate the prevalence, risk factors, clinical patterns, and outcomes of olanzapine-associated hepatotoxicity in bipolar disorder patients. Methods: We conducted a multicenter retrospective cohort study was conducted across three tertiary hospitals, enrolling bipolar disorder patients (DSM-5 criteria) treated with olanzapine between January and December 2023. Demographics, treatment details, and laboratory data were extracted from electronic records. Univariate and multivariate logistic regression analyses identified risk factors for olanzapine-associated liver injury. Results: Hepatotoxicity, defined according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria, was the primary endpoint and occurred in 118 of 487 hosptialized patients (24.2%), with the majority classified as mild (19.3%). Injury patterns were predominantly mixed in mild-to-moderate cases and hepatocellular in severe cases. Multivariate analysis identified higher daily dosage (OR: 1.070, 95%CI: 1.006-1.138, Conclusion: This real-world observational study demonstrates a significant association between olanzapine and hepatotoxicity in hospitalized bipolar disorder patients. Our findings highlight the importance of regular liver function monitoring during olanzapine treatment, particularly in patients receiving higher daily doses, and suggest that dose management strategies may play a key role in mitigating hepatotoxicity risk in routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.